This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Retinal Dystrophy
  • /
  • Efficacy and safety of voretigene neparvovec (AAV2...
Journal

Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

Read time: 1 mins
Published:25th Aug 2017
Author: Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A et al.
Source: The Lancet
Availability: Free full text
Ref.:Lancet. 2017 Aug 26;390(10097):849-860.
DOI:10.1016/S0140-6736(17)31868-8
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest